Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 1999-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The aim of this trial is to compare two different active treatment regimens of biphasic insulin aspart in subjects with type 2 diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Duration of diabetes for longer than 12 months

• Body mass index (BMI) below 35.0 kg/m^2

• HbA1c below 11.0 %

• Treatment with BHI (biphasic human insulin) 20 or 30 twice daily for at least three months and in the last month as sole anti-diabetic treatment (i.e., no additional oral hypoglycaemic medication or daily use of short-acting insulin supplement)

Exclusion Criteria:

• Current treatment with agents affecting glucose metabolism

• History of drug or alcohol dependence

• Impaired hepatic function

• Impaired renal function

• Cardiac disease

• Proliferative retinopathy

• Recurrent severe hypoglycaemia or advanced neuropathy